Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
11-valent Recombinant Human Papillomavirus Vaccine in Chinese Women Aged 18-45 Years
NCT05262010Phase 3Active, not recruiting
- Sponsor
- Serum Institute of India
- Start
- Jun 2022
- Primary completion
- Jun 2028
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of 11-valent recombinant human papilloma virus vaccine in human papillomavirus infection, HPV-related carcinoma, sponsored by Serum Institute of India. Started Jun 2022; status: active, not recruiting.
02
Drugs
11-valent recombinant human papilloma virus vaccine
03
Conditions
human papillomavirus infectionHPV-related carcinoma
Beyond the preview
Go deeper on NCT05262010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05262010.